Physician profile
Jared Thomas Geist
NPI 1700078276
$4,739.42
in general payments reported to CMS, 2019-2025
31 companies · $1,338 in 2025
The $1,338 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $260 · 2020: $165 · 2021: $81.14 · 2022: $709 · 2023: $1,073 · 2024: $1,113 · 2025: $1,338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,479 · Education: $45.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,479.14 |
| Education | $45.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,292.12 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $619.14 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Janssen Biotech, INC. | $448.02 | 2022-2025 | Stelara, Tremfya, Simponi |
| Pfizer INC. | $344.20 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $330.93 | 2019-2025 | Entyvio |
| Endogastric Solutions, INC | $202.55 | 2019-2020 | |
| Genzyme Corporation | $155.16 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $136.09 | 2019-2025 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $126.94 | 2022-2025 | Dupixent |
| Madrigal Pharmaceuticals | $114.74 | 2025 | Rezdiffra |
| Merck Sharp & Dohme LLC | $91.90 | 2022-2024 | Dificid |
| Gilead Sciences, INC. | $86.26 | 2022-2025 | |
| Lucid Diagnostics INC. | $76.55 | 2024 | |
| Ardelyx, INC. | $71.18 | 2023-2025 | Ibsrela |
| Lilly USA, LLC | $69.91 | 2024-2025 | Omvoh |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $69.28 | 2024-2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $60.16 | 2023 | Rebyota, Cimzia |
| Nestle Healthcare Nutrition INC. | $57.64 | 2022 | |
| Ironwood Pharmaceuticals, INC | $55.04 | 2022-2023 | Linzess |
| Qol Medical, LLC | $53.57 | 2024-2025 | Sucraid, Sucraid |
| Celltrion USA INC. | $48.41 | 2024-2025 | Vegzelma, Zymfentra |
| Aimmune Therapeutics, INC. | $45.69 | 2025 | Zenpep |
| Medtronic, INC. | $31.06 | 2025 | Gi Genius |
| Daiichi Sankyo INC. | $28.16 | 2023 | Injectafer |
| Boston Scientific Corporation | $27.08 | 2025 | Apollo Esg Nxt System |
| Biocon Biologics INC | $24.44 | 2025 | Yesintek |
| Ipsen Biopharmaceuticals, INC | $19.21 | 2025 | Iqirvo |
| Celgene Corporation | $15.52 | 2023 | Zeposia |
| Shire North American Group INC | $14.96 | 2019 | |
| Amgen INC. | $12.79 | 2023 | Avsola, Amjevita |
| Organon LLC | $10.72 | 2025 | Hadlima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Geist listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.